121 related articles for article (PubMed ID: 3051406)
21. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Chari RV
Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
[TBL] [Abstract][Full Text] [Related]
22. Antibodies in the therapy of colon cancer.
Welt S; Ritter G
Semin Oncol; 1999 Dec; 26(6):683-90. PubMed ID: 10606261
[TBL] [Abstract][Full Text] [Related]
23. Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential.
Epstein AL; Marder RJ; Winter JN; Stathopoulos E; Chen FM; Parker JW; Taylor CR
Cancer Res; 1987 Feb; 47(3):830-40. PubMed ID: 3542194
[TBL] [Abstract][Full Text] [Related]
24. [Application of monoclonal antibodies to bone marrow transplantation].
Morishima Y
Gan To Kagaku Ryoho; 1988 May; 15(5):1693-701. PubMed ID: 3285796
[TBL] [Abstract][Full Text] [Related]
25. Combination of chemotherapy and monoclonal antibodies for the treatment of lymphoma.
Thieblemont C; Coiffier B
Int J Hematol; 2002 Dec; 76(5):394-400. PubMed ID: 12512833
[TBL] [Abstract][Full Text] [Related]
26. Antitumor vaccination: where we stand.
Bocchia M; Bronte V; Colombo MP; De Vincentiis A; Di Nicola M; Forni G; Lanata L; Lemoli RM; Massaia M; Rondelli D; Zanon P; Tura S
Haematologica; 2000 Nov; 85(11):1172-206. PubMed ID: 11074658
[TBL] [Abstract][Full Text] [Related]
27. Establishment of new SCID and nude mouse models of human B leukemia/lymphoma and effective therapy of the tumors with immunotoxin and monoclonal antibody: marked difference between the SCID and nude mouse models in the antitumor efficacy of monoclonal antibody.
Kawata A; Yoshida M; Okazaki M; Yokota S; Barcos M; Seon BK
Cancer Res; 1994 May; 54(10):2688-94. PubMed ID: 8168098
[TBL] [Abstract][Full Text] [Related]
28. Application of monoclonal antibodies to tumor diagnosis and therapy.
Rosen ST; Winter JN; Epstein AL
Ann Clin Lab Sci; 1983; 13(3):173-84. PubMed ID: 6347022
[TBL] [Abstract][Full Text] [Related]
29. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
[TBL] [Abstract][Full Text] [Related]
30. The Challenge of Developing New Therapies for Childhood Cancers.
Balis FM
Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
[TBL] [Abstract][Full Text] [Related]
31. [Rituximab].
Okamoto R; Maeda Y; Sasaki T
Gan To Kagaku Ryoho; 2003 Aug; 30(8):1085-93. PubMed ID: 12938262
[TBL] [Abstract][Full Text] [Related]
32. [Use of antibodies or their fragments for the treatment of tumors].
Douillard JY; Chatal JF
Bull Cancer; 1998 Nov; 85(11):951-9. PubMed ID: 9951422
[TBL] [Abstract][Full Text] [Related]
33. Monoclonal antibodies in cancer treatment: where do we stand after 10 years?
Boven E; Pinedo HM
Radiother Oncol; 1986 Feb; 5(2):109-17. PubMed ID: 3517970
[TBL] [Abstract][Full Text] [Related]
34. The generation of monoclonal anti-idiotype antibodies to human B cell-derived leukemias and lymphomas.
Giardina SL; Schroff RW; Kipps TJ; Woodhouse CS; Abrams PG; Rager HC; Morgan AC; Foon KA
J Immunol; 1985 Jul; 135(1):653-8. PubMed ID: 3873497
[TBL] [Abstract][Full Text] [Related]
35. Target therapy of cancer: implementation of monoclonal antibodies and nanobodies.
Majidi J; Barar J; Baradaran B; Abdolalizadeh J; Omidi Y
Hum Antibodies; 2009; 18(3):81-100. PubMed ID: 19729803
[TBL] [Abstract][Full Text] [Related]
36. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
37. Monoclonal antibody therapy of lymphoproliferative disorders.
Kuzel TM; Winter JN; Rosen ST; Zimmer AM
Oncology (Williston Park); 1990 Mar; 4(3):77-84; discussion 84, 89-90, 92-3. PubMed ID: 2144449
[TBL] [Abstract][Full Text] [Related]
38. Lymphokines, monoclonal antibodies, and other biological response modifiers in the treatment of cancer.
Oldham RK; Thurman GB; Talmadge JE; Stevenson HC; Foon KA
Cancer; 1984 Dec; 54(11 Suppl):2795-806. PubMed ID: 6437660
[TBL] [Abstract][Full Text] [Related]
39. The history and rationale for monoclonal antibodies in the treatment of hematologic malignancy.
Dillman RO
Curr Pharm Biotechnol; 2001 Dec; 2(4):293-300. PubMed ID: 11762411
[TBL] [Abstract][Full Text] [Related]
40. Monoclonal antibody therapy of haematological malignancies.
Dearden C
BioDrugs; 2002; 16(4):283-301. PubMed ID: 12196040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
